Artelo Biosciences grants stock options to director

Artelo Biosciences granted director Connie Matsui a stock option covering 136 shares of common stock at an exercise price of $1.15 per share, expiring on July 17, 2036.

Rhea-AI Filing Summary

Artelo Biosciences granted director Connie Matsui a stock option covering 136 shares of common stock at an exercise price of $1.15 per share, expiring on July 17, 2036. The option vests 100% on the earlier of the one-year anniversary of the July 17, 2026 Vesting Commencement Date or the day prior to the next annual stockholders’ meeting following that date, contingent on her continued service as a Service Provider.

Insider Trade Summary

Grant/Award: 136 shares

Grant/Award 1 txn

Insider MATSUI CONNIE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	136	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 136 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.

Key Figures

Option shares granted: 136.0000 shares Exercise price: $1.1500 per share Underlying common shares: 136.0000 shares +3 more

6 metrics

Option shares granted 136.0000 shares Stock option grant to director Connie Matsui

Exercise price $1.1500 per share Conversion or exercise price of the stock option

Underlying common shares 136.0000 shares Common stock underlying the reported stock option

Shares following transaction 136.0000 derivative securities Total option shares held after this grant

Option expiration date 2036-07-17 Expiration date of the granted stock option

Vesting Commencement Date July 17, 2026 Date from which the one-year vesting period is measured

Key Terms

Stock Option (right to buy), Vesting Commencement Date, Service Provider, annual meeting of the Issuer's stockholders

4 terms

Stock Option (right to buy) financial

"Security title reported as "Stock Option (right to buy)" for this grant"

Vesting Commencement Date financial

""Vesting Commencement Date" shall mean July 17, 2026."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

annual meeting of the Issuer's stockholders financial

"vest on the day prior to the date of the annual meeting of the Issuer's stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Artelo Biosciences (ARTL) report for director Connie Matsui?

Artelo Biosciences reported that director Connie Matsui received a grant of stock options for 136 shares of common stock. These options have a $1.15 exercise price and expire on July 17, 2036, with vesting tied to continued service.

How many stock options did Connie Matsui receive from Artelo Biosciences (ARTL)?

Connie Matsui was granted a stock option covering 136 shares of Artelo Biosciences common stock. After this grant, her reported derivative holdings for this option total 136.0000 shares, reflecting the entire award in this transaction.

What is the exercise price of Connie Matsui’s Artelo Biosciences (ARTL) stock options?

The granted stock option allows purchase of Artelo Biosciences common stock at an exercise price of $1.15 per share. This conversion price applies to all 136 underlying shares associated with the option reported in the transaction.

When do Connie Matsui’s Artelo Biosciences (ARTL) stock options vest?

All option shares vest 100% on the earlier of the one-year anniversary of the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholders’ meeting after that date, subject to her continued status as a Service Provider.

What is the expiration date of the stock options granted to Connie Matsui by Artelo Biosciences (ARTL)?

The reported stock option granted to Connie Matsui expires on July 17, 2036. She may exercise the option to buy up to 136 shares at $1.15 per share any time before that expiration, subject to vesting and plan terms.

Were any Artelo Biosciences (ARTL) shares bought or sold on the market in this Connie Matsui transaction?

No market purchase or sale is reported; the transaction is a grant of a stock option. Matsui acquired derivative rights to 136 shares at a fixed exercise price, with no per-share cash price paid for the grant itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/21/2026 - 06:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATSUI CONNIE

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.15	07/17/2026		A		136		(1)	07/17/2036	Common Stock	136	$0.00	136	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)